# Targinta secures patents in Europe, China and the USA for integrin α10 antibodies in aggressive cancers

**Targinta (subsidiary of Xintela) announces that the company has been granted new patents in three major markets for its integrin α10 antibody technology: a European patent for triple-negative breast cancer, a Chinese patent that also covers other aggressive cancers, and a second US patent for the diagnosis of brain tumours.**

The European Patent Office has granted EP 3 956 360, which covers antibodies that bind integrin α10 and inhibit the growth of cancer cells, for the treatment of triple-negative breast cancer (TNBC), as well as methods for diagnosis and prognosis. The patent has unitary effect in 18 EU member states, is also in force in the United Kingdom and Switzerland, and can be maintained until April 2040.

The China National Intellectual Property Administration has granted patent ZL 202080043354.8, covering defined integrin α10 antibodies for the treatment and diagnosis of TNBC and other aggressive cancers, including lung and pancreatic cancer. This patent is also in force until April 2040.

The US Patent and Trademark Office has issued US 12,806,280, Targinta's second US patent in the patent family for tumours of the central nervous system. The patent covers methods for detecting integrin α10 in samples from the central nervous system in order to identify tumours. Covered tumour types include glioma and glioblastoma, and the patent is in force until September 2037. The patent family is also granted in Europe, Japan and several other countries.

“These patents provide our integrin α10 antibodies broader protection and strengthen our patent position in several major markets. Together with our product patent applications for TARG9 and TARG10, this gives Targinta and future partners a strong foundation for exclusivity in some of the most aggressive and difficult-to-treat cancers”, says Evy Lundgren-Åkerlund, CEO of Targinta.

**For further information, please contact:** Evy Lundgren-Åkerlund, CEO, evy@xintela.se, +46 46 275 65 00

**About Xintela and Targinta**
Xintela (XINT) is a publicly-traded clinical-stage biopharma company developing cutting edge medical products in stem cell therapy and targeted cancer therapy. Xintela’s proprietary technology uses the stem cell marker integrin α10β1 to select and quality-assure stem cells in the product XSTEM®, which has shown safety and disease modifying effect in a clinical study on knee osteoarthritis as well as safety in a clinical study on difficult-to-heal leg ulcers.
Xintela’s wholly owned subsidiary Targinta develops First-in-Class therapeutic antibodies targeting integrin α10β1. TARG9, an Antibody-Drug Conjugate (ADC), and TARG10, a function blocking antibody, are in preclinical development for the treatment of aggressive, difficult-to-treat cancers including glioblastoma, triple-negative breast cancer and sarcoma.
Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm. Xintela’s Certified Adviser is Västra Hamnen Corporate Finance AB.